Roche to Buy InterMune for $8.3B, Adds Lung Drug

Aug. 25 (Bloomberg) -- Roche is strengthening its portfolio of medicines for respiratory ailments with an agreement to buy InterMune for $8.3 billion in cash. Olivia Sterns reports on “In The Loop.” (Source: Bloomberg)
RBA Decision: Will They Keep Rates Steady?
04:42 - JPMorgan Australia Vice President of Macro Sales Laura Fitzsimmons discusses the RBA interest rate decision due later today, commodity prices and the Greek stock market reopening. She speaks to Bloomberg’s Shery Ahn on “First Up.” (Source: Bloomberg)
  • Korean Inflation Rose 0.7% in July
  • Brent Falls Below $50 for First Time Since January
  • The Top Three Stocks to Watch in Asia Today